Biogen to spin off hemophilia drug business into a public company
May 03, 2016 at 07:43 AM EDT
May 3 (Reuters) - Drugmaker Biogen Inc said on Tuesday it intends to spin off its hemophilia drug business as an independent, publicly traded company in a tax-free transaction.